Patents by Inventor Brian W. Metcalf

Brian W. Metcalf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aza spiro alkane derivatives as inhibitors of metalloproteases
    Patent number: 10226459
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 12, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • PYRIMIDINONES AS PI3K INHIBITORS
    Publication number: 20180362546
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: April 23, 2018
    Publication date: December 20, 2018
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    Publication number: 20180354929
    Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Application
    Filed: January 8, 2018
    Publication date: December 13, 2018
    Inventors: Brian W. Metcalf, Chihyuan Chuang
  • Crystalline forms of a PI3K inhibitor
    Patent number: 10125150
    Abstract: The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 13, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 10100040
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 16, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • CRYSTALLINE FORMS OF A PI3K INHIBITOR
    Publication number: 20180258105
    Abstract: The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 13, 2018
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 10017491
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 10, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Chihyuan Chuang
  • AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases
    Publication number: 20180153882
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Application
    Filed: September 29, 2017
    Publication date: June 7, 2018
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • Crystalline forms of a PI3K inhibitor
    Patent number: 9988401
    Abstract: The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino) ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: June 5, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 9981939
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 29, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Pyrimidinones as PI3K inhibitors
    Patent number: 9975907
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 22, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 9957250
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 1, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Jason R. Harris, Zhe Li, Stephen L. Gwaltney, II
  • Amido compounds and their use as pharmaceuticals
    Patent number: 9957229
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: May 1, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian
  • Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines
    Patent number: 9908888
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 6, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • Amido Compounds And Their Use As Pharmaceuticals
    Publication number: 20170334847
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Application
    Filed: May 23, 2017
    Publication date: November 23, 2017
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian
  • AZA spiro alkane derivatives as inhibitors of metalloproteases
    Patent number: 9801877
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: October 31, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • Pyrazolopyridine pyrazolopyrimidine and related compounds
    Patent number: 9695166
    Abstract: In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: July 4, 2017
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Chul Yu, Calvin Yee, Stephen L. Gwaltney, II, Brian W. Metcalf, Steven Richards, Matthew A. Lardy, Lina Setti, Hing Sham
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20170174654
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: February 28, 2017
    Publication date: June 22, 2017
    Inventors: Brian W. METCALF, Chihyuan Chuang
  • Amido compounds and their use as pharmaceuticals
    Patent number: 9670154
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 6, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian
  • SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    Publication number: 20170107199
    Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 20, 2017
    Inventors: Brian W. METCALF, Chihyuan CHUANG, Jeffrey WARRINGTON, Matthew P. JACOBSON